...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Heartdrug: excellence in cardiovascular trials >Long-term treatment with angiotensin-converting enzyme inhibitors, beta-blockers or a combination of angiotensin-converting enzyme inhibitors and beta-blockers in low-risk patients after acute myocardial infarction: The ABC study
【24h】

Long-term treatment with angiotensin-converting enzyme inhibitors, beta-blockers or a combination of angiotensin-converting enzyme inhibitors and beta-blockers in low-risk patients after acute myocardial infarction: The ABC study

机译：急性心肌梗死后低危患者长期使用血管紧张素转换酶抑制剂，β受体阻滞剂或血管紧张素转换酶抑制剂和β受体阻滞剂的长期治疗：ABC研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Therapy with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers improves the prognosis of patients with impaired ventricular function, and of patients with symptoms of heart failure after acute myocardial infarction. Long-term treatment strategies for low-risk patients after acute myocardial infarction have not as yet been elucidated by clinical studies. Objective: The objective of this study is to deliver evidence of a possible additional, long-term effect from the combination of ACE inhibitors and beta-blockers, as compared with monotherapy with ACE inhibitors or beta-blockers, for patients after acute myocardial infarction but with only slightly restricted left ventricular function, and without symptoms of heart failure. Methods: In 160 patients who have suffered myocardial infarction, but do not have appreciable impairment of left ventricular ejection fraction, i.e. ejection fraction < greater-than-or-equal-to > 40%, or symptoms of heart failure, we shall administer eithermonotherapy with ramipril or metoprolol, or combination therapy in the form of ramipril and metoprolol. The primary end point will be the left ventricular ejection fraction after 18 months. Secondary end points will be mortality, arrhythmia, cardiac stress tolerance, development of heart failure and the need for revascularization. Copyright < copyright > 2000 S. Karger AG, Basel.
机译：背景：血管紧张素转换酶（ACE）抑制剂和β受体阻滞剂的治疗可改善心室功能受损的患者以及急性心肌梗死后出现心力衰竭症状的患者的预后。临床研究尚未阐明急性心肌梗死后低危患者的长期治疗策略。目的：本研究的目的是为急性心肌梗死后的患者提供证据，证明与ACE抑制剂或β受体阻滞剂的单药治疗相比，ACE抑制剂和β受体阻滞剂的组合可能产生额外的长期作用左心室功能仅受轻微限制，无心力衰竭症状。方法：在160例患有心肌梗塞但左心室射血分数没有明显损害（即射血分数<大于等于> 40％或心力衰竭症状）的患者中，我们应采用单药治疗雷米普利或美托洛尔，或雷米普利和美托洛尔形式的联合治疗。主要终点将是18个月后的左心室射血分数。次要终点将是死亡率，心律不齐，心脏压力耐受性，心力衰竭的发展和血运重建的需要。版权<版权> 2000 S. Karger AG，巴塞尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号